Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer

NCT03179943 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT03179943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03179943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 27, 2017
Completion date
July 31, 2022
Enrollment
21 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma